Research
Excludes commercial-in-confidence projects.
Development of a new therapy for glioblastoma based on chimeric antigen receptor (CAR)-T cells, Tour de Cure Ltd, 01/01/2021 - 31/12/2022
Checkpoint blockade immunotherapy in melanoma: getting tumour-killing T cells to their site of action, Royal Adelaide Hospital, 01/01/2016 - 31/03/2017
Research
Research outputs for the last seven years are shown below.
Open access indicates that an output is open access.
Year | Output |
---|---|
2021 |
Open access
3
2
22
|
2021 |
Open access
1
2
2
|
2021 |
7
6
|
2021 |
1
|
2021 |
Open access
3
|
2021 |
Open access
2
2
2
|
2021 |
Open access
3
3
8
|
2020 |
6
5
2
|
2020 |
Open access
13
12
5
|
2020 |
1
1
|
2020 |
Open access
4
4
11
|
2020 |
Open access
1
1
6
|
2020 |
5
5
2
|
2019 |
Open access
20
20
5
|
2019 |
14
17
2
|
2019 |
Open access
5
4
|
2019 |
7
7
3
|
2019 |
3
2
|
2019 |
58
59
9
|
2019 |
Open access
11
12
1
|
2019 |
Open access
9
9
20
|
2018 |
Open access
|
2018 |
Open access
47
41
9
|
2018 |
15
15
5
|
2018 |
Open access
33
33
3
|
2018 |
469
445
78
|
2018 |
Open access
7
7
10
|
2017 |
24
19
|
2017 |
Open access
14
14
2
|
2017 |
Open access
135
125
12
|
2017 |
Open access
9
9
2
|
2017 |
6
6
|
2017 |
Open access
21
22
3
|
2016 |
8
8
1
|
2016 |
Open access
177
176
11
|
2016 |
1
|
2016 |
Open access
31
31
2
|
2015 |
Open access
16
15
5
|
2015 |
1
1
|
2015 |
69
63
19
|
2015 |
25
26
1
|
2015 |
11
10
|
2015 |
15
14
1
|
2014 |
Open access
195
185
24
|
2014 |
16
13
1
|
2014 |
Open access
2
2
6
|
2014 |
Open access
20
19
|
2013 |
Open access
55
49
15
|
2013 |
Open access
4
|
2013 |
Open access
133
127
5
|
2013 |
Open access
2
3
|
2013 |
Open access
18
18
1
|
2013 |
Open access
7
6
|
2012 |
Open access
77
75
|
2012 |
Open access
|
2012 |
7
7
3
|
2012 |
Open access
728
673
32
|
2012 |
5
5
12
|
2011 |
Open access
104
95
|
2011 |
1
1
|
2011 |
2
2
|
2011 |
Open access
18
17
|
2011 |
33
30
|
2011 |
12
14
|
2011 |
Open access
9
9
|
2011 |
Open access
57
57
|
2010 |
Open access
103
102
|
2010 |
Open access
5
5
|
2010 |
4
4
|
2010 |
Open access
10
10
|
2009 |
Open access
27
24
|
2009 |
27
26
|
2009 |
Open access
14
14
|
2009 |
53
51
|
2009 |
Open access
119
165
|
2009 |
29
25
|
2009 |
26
28
|
2008 |
9
7
|
2008 |
27
28
|
External engagement & recognition
Organisation | Country |
---|---|
Adelaide Cancer Centre | AUSTRALIA |
Adelaide Radiotherapy Centre | AUSTRALIA |
Angeles Clinic and Research Institute | UNITED STATES |
Austin Hospital | AUSTRALIA |
Australian National University | AUSTRALIA |
Bayer | UNITED STATES |
Baylor College of Medicine | UNITED STATES |
Bristol-Myers Squibb, US | AUSTRALIA |
Centro Oncologico de Rosario | ARGENTINA |
Clinical Network Services | AUSTRALIA |
Copenhagen University Hospital | DENMARK |
CSIRO Australia (Commonwealth Scientific Industrial Research Organisation) | AUSTRALIA |
Department of Health | AUSTRALIA |
Duke University | UNITED STATES |
Eli Lilly | AUSTRALIA |
Flinders Medical Centre | AUSTRALIA |
Flinders University | AUSTRALIA |
Garvan Institute of Medical Research | AUSTRALIA |
GenesisCare | AUSTRALIA |
GlaxoSmithKline | AUSTRALIA |
Griffith University | AUSTRALIA |
Hanson Institute | AUSTRALIA |
Hebrew University | MEXICO |
Hospital Clinic Barcelona | SPAIN |
Hospital Universitario | UNITED STATES |
Houston Methodist Hospital | UNITED STATES |
Institute of Medical and Veterinary Science | AUSTRALIA |
Lipotek Pty Ltd | AUSTRALIA |
Ludwig Institute for Cancer Research | AUSTRALIA |
Mayo Clinic | UNITED STATES |
Monash University | AUSTRALIA |
Motherson Innovations Australia | AUSTRALIA |
Netherlands Cancer Institute | NETHERLANDS |
New York Medical College | UNITED STATES |
New York University | UNITED STATES |
Novartis Pharmaceuticals Corporation | UNITED STATES |
Nucleus Network | AUSTRALIA |
Olivia Newton John Cancer Research Institute | AUSTRALIA |
Osaka Prefecture University | JAPAN |
Peter MacCallum Cancer Centre | AUSTRALIA |
Pfizer Oncology | UNITED STATES |
PharmAust | AUSTRALIA |
Pontifical Catholic University of Rio Grande do Sul (PUCRS) | BRAZIL |
Prince of Wales Hospital | AUSTRALIA |
Private Individual | AUSTRALIA |
QIMR Berghofer Medical Research Institute | AUSTRALIA |
Queen Elizabeth Hospital | AUSTRALIA |
Queensland Institute of Medical Research | AUSTRALIA |
Roche Diagnostics | SWITZERLAND |
Royal Adelaide Hospital | AUSTRALIA |
Royal Darwin Hospital | AUSTRALIA |
Royal Melbourne Hospital | AUSTRALIA |
SA Pathology | AUSTRALIA |
Sarah Cannon Research Institute | UNITED STATES |
Sarcoma Research Group | AUSTRALIA |
Seoul National University | KOREA, REPUBLIC OF (SOUTH) |
Sir Charles Gardiner Hospital | AUSTRALIA |
South Australian Health and Medical Research Institute (SAHMRI) | AUSTRALIA |
Southern Medical Day Care Centre | AUSTRALIA |
Taipei Veterans General Hospital | TAIWAN |
TBG Diagnostics | AUSTRALIA |
The Royal Marsden NHS Foundation Trust | UNITED KINGDOM |
University Clinic Schleswig-Holsteinl | GERMANY |
University Hospital Schleswig-Holstein | GERMANY |
University Medical Centre Freiburg | GERMANY |
University of Adelaide | AUSTRALIA |
University of British Columbia | CANADA |
University of Colorado | UNITED STATES |
University of Freiburg | GERMANY |
University of Melbourne | AUSTRALIA |
University of New South Wales | AUSTRALIA |
University of Newcastle | AUSTRALIA |
University of North Carolina at Chapel Hill | UNITED STATES |
University of Pennsylvania | UNITED STATES |
University of Pittsburgh | UNITED STATES |
University of Queensland | AUSTRALIA |
University of South Australia | AUSTRALIA |
University of South Florida | UNITED STATES |
University of Sydney | AUSTRALIA |
University of Texas | UNITED STATES |
University of Utah | UNITED STATES |
University of Western Australia | AUSTRALIA |
University of Zurich | SWITZERLAND |
Vall d'Hebron University Hospital | SPAIN |
Virax Holdings Limited | AUSTRALIA |
Yonsei University College of Medicine | KOREA, REPUBLIC OF (SOUTH) |
Zucero Therapeutics | AUSTRALIA |
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
Finding out how well chimeric antigen receptor (CAR)-T cells kill brain tumour cells | Current |
Development and evaluation of ovine polyclonal antibody therapies for the treatment of severe influenza infection and bacterial sepsis | Completed |
Dissecting the mechanisms involved in the induction of immunity to recombinant fowlpox virus | Completed |
Evaluation of the immunomodulatory properties of dasatinib for improved application in combinatorial immunotherapy regimens | Completed |
Optimising CAR T cell manufacturing for solid cancers | Completed |
The use of biomaterials to investigate and modulate innate and adaptive immunity | Completed |
Vasculogenic mimicry: regulation and function in melanoma | Completed |